Skip to main content

What the FDA labels say about taking them together

Dabrafenib and gemfibrozil

Gemfibrozil's FDA label of April 10, 2026 names dabrafenib in its drug interactions section; the dabrafenib label PlainMeds reads does not name gemfibrozil. The gemfibrozil label: “(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8.”

Check it at the source: the dabrafenib FDA label on DailyMed (effective May 20, 2026, Novartis Pharmaceuticals Corporation); the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC).

What does the dabrafenib label say about gemfibrozil?

Dabrafenib's label (effective May 20, 2026) does not name gemfibrozil in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Tafinlar), Novartis Pharmaceuticals Corporation, effective May 20, 2026 (SPL set fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea), via openFDA; the full label on DailyMed

What does the gemfibrozil label say about dabrafenib?

Gemfibrozil label, drug interactions

(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8 (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone).

Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Dabrafenib generic labelers
27Gemfibrozil generic labelers
DabrafenibGemfibrozil
Labeled forLung cancerHigh cholesterol, Heart attack and coronary artery disease
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.104 per tablet 600 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?